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Type and screen testing is used to determine blood 
compatibility and identify clinically significant antibodies 
affecting blood transfusion compatibility.
Type and screen testing was suspected to be 
unnecessarily ordered in our organization. Type and 
screen tests are active for three days from the date the 
specimen is collected, yet many patients receive orders 
for repeat testing well in advance of the sample’s 
expiration. Effects of CDSS have not been assessed 
when applied specifically to type and screen tests. 
The specific aims of our study were to:
• Determine the number of unnecessarily ordered type 
and screen tests prior to and after implementation of a 
CDSS.
• Determine the difference in estimated costs of 
unnecessary type and screen testing based on testing 
materials and labor expenses before versus after 
implementation of a CDSS.
• Describe the unnecessary type and screen test 
ordering practices of different provider type(s) (i.e., 
physician, advanced practice nurse [APRN], and 
physician assistant [PA]) before and after 
implementation of a CDSS.
There were a total of 26,206 pre- and 25,053 post-
intervention specimens. Significantly fewer unnecessary 
type and screen tests were ordered after the intervention 
(12.3%, n=3,073) than before (14.1%, n=3,691; p<0.001; 
Table 1), representing a reduction of 16.7%
The results demonstrated an estimated yearly savings of 
$142,612 (Table 2). The majority of the tests were 
ordered by physicians (85.3% before and 83.1% after the 
intervention) compared to APRNs and PAs (Table 3). 
Our study demonstrated that a CDSS impacted a variety 
of provider types, reduced unnecessary phlebotomy tests, 
and achieved yearly cost savings. To further improve test 
ordering practices of all provider types, we recommend 
additional interventions such as organizational support, 
education, audits, and feedback.
Unnecessary laboratory testing continues in health care 
and contributes to excessive health spending without 
adding value. Phlebotomy testing is one example of how 
providers can reduce waste and control healthcare costs 
for low-cost, high-frequency tests.
In this era of precision healthcare, the upshot of ordering 
the right test, at the right time, for the right reason can 
reduce cost, reduce waste, improve quality and 
satisfaction for patients.
Our study illustrates the effectiveness of CDSS as a 
means of reducing unnecessary health care services. 
CPOE is widely used in a variety of health care settings 
and can incorporate CDSS to guide all provider types to 
make judicious decisions at the time of care. 
Until the establishment of national quality measures 
aimed to control the number of low-cost, high-frequency 
tests, health systems must find a way to reduce 
unnecessary health services. 
Design: Our value improvement initiative used a 
retrospective separate-sample pretest posttest design.
Sample: The total number of appropriate and 
unnecessarily ordered type and screen tests from the 
three-month pre-intervention and three-month post-
intervention period was used to determine effectiveness 
of the CDSS. All unnecessarily ordered tests from the pre-
and post- intervention periods were used for cost 
estimation. Random selections of 801 tests before and 
801 tests after the intervention were used to describe 
ordering practices by provider type.
Setting: Large Mid-Atlantic urban academic medical 
center.
Intervention: A CDSS to promote appropriate test 
ordering was embedded in our computerized order entry 
(CPOE) system. The CDSS appears when a type and 
screen test is ordered informing the provider of the date 
and time the current test expires (Figure 1).
Measurement: The total number of type and screen tests 
was captured in a monthly aggregate report. 
Unnecessary tests are those ordered and preformed prior 
to the previous test’s expiration. Using data from the 
CPOE, laboratory information, and transfusion software 
systems, a customized report identified the unnecessary 
tests.. Estimated cost of unnecessary tests used a 
combination of direct costs and labor costs. Our office of 
credentialing provided the total number of each provider 
type employed at our medical center.
Analysis: Pre-intervention and post-intervention data 
were compared using chi-square, time-drive activity-
based costing estimate, and descriptive statistics. Level of 
significance was set at 0.05.
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Overuse of phlebotomy testing offers little to improve 
patient outcomes but may subject patients to additional 
morbidity. As a value-based system in healthcare 
continues to evolve, providers and healthcare 
organizations need to reduce non-value-added care 
without compromising quality. Low-cost, high-frequency 
tests are often ordered recurrently, unnecessarily, and 
contribute to the high cost of health care. Reducing 
unnecessary phlebotomy tests can cut costs without 
compromising quality. 
Clinical decision support systems (CDSSs) are 
applications embedded in the electronic health record 
with specific patient information that appear at the time of 
ordering to assist health care professionals in decision-
making to improve care. 
Adoption of CDSSs have been successful in reducing 
unnecessary radiologic imaging, overuse of antibiotics, 
and Clostridium dificile testing.
Total n (%) Appropriate order n (%)
Unnecessary 
order n (%) Statistic X
2 p-value
Pre-CDS 
tool 26206 (100) 225151(85.9) 3691 (14.1)
36.98 <0.001
Post-CDS 
tool 25053 (100) 21980 (87.7) 3073 (12.3)
Table 1 Unnecessary Type and Screen Tests Ordered Before 
Versus After Implementation of a CDSS
Table 3 Unnecessary Type and Screen Tests Ordered by 
Provider Type Before Versus After Implementation of a CDSS
Table 2 Estimated Cost of Unnecessary Type and Screen 
Tests Ordered Before Versus After CDSS
Figure 1 CDSS for Type and Screen Test 
Total n (%) Physician n (%) APRN
n (%)
PA n (%)
Pre-CDSS 801 (50) 683 (85.3) 51 (6.4) 67 (8.4)
Post-CDSS 801 (50) 666 (83.1) 80 (10) 55 (6.9)
Total 1602 (100) 1349 (84.2) 131 (8.2) 122 (7.6)
Pre-CDSS Post-CDSS
Estimated cost of 
unnecessary tests 




cost of unnecessary 
tests
$851,744.00 $709,132.00
Estimated yearly 
savings
$142,612
